CBD Showed Protective Effects Against Parkinson-Like Symptoms in Mice, Especially as Preventive Treatment

In mice given low-dose reserpine to progressively develop Parkinson-like symptoms, CBD (0.5 mg/kg) delayed the appearance of catalepsy and abnormal mouth movements. CBD also prevented the loss of tyrosine hydroxylase (TH) labeling in the substantia nigra, indicating protection of dopamine-producing neurons. Preventive CBD treatment (started before symptoms) was more effective than concurrent treatment (started alongside reserpine).

Two experimental approaches in mice: concurrent CBD administration during Parkinson development, and preventive CBD pre-administration. Low-dose repeated reserpine (0.1 mg/kg) was used as a progressive Parkinson model. Behavioral (catalepsy, vacuous chewing) and neuronal (TH immunolabeling) outcomes were measured.

Most Parkinson research uses acute, high-dose toxin models. This study used a progressive model that better mimics the slow disease course in humans, and found CBD was protective, particularly when started early.

Parkinson disease treatment remains focused on symptom management after diagnosis. The finding that CBD worked better as a preventive raises the question of whether early cannabinoid intervention could slow neurodegeneration before clinical symptoms appear.

Mouse model, and the reserpine-based model does not fully replicate human Parkinson pathology (no alpha-synuclein aggregation). Single low dose of CBD tested. No assessment of non-motor Parkinson symptoms.